INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2017. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,924,000 | +1.9% | 56,138 | +23.9% | 0.01% | +8.3% |
| Q2 2023 | $2,870,000 | -12.0% | 45,319 | -24.8% | 0.01% | -14.3% |
| Q1 2023 | $3,263,000 | +2.3% | 60,262 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $3,189,000 | +0.0% | 60,262 | -12.0% | 0.01% | 0.0% |
| Q3 2022 | $3,188,000 | -31.5% | 68,509 | -15.9% | 0.01% | -30.0% |
| Q2 2022 | $4,652,000 | -26.9% | 81,502 | -21.6% | 0.02% | -9.1% |
| Q1 2022 | $6,361,000 | +27.7% | 103,958 | +9.2% | 0.02% | +29.4% |
| Q4 2021 | $4,981,000 | +40.4% | 95,158 | 0.0% | 0.02% | +30.8% |
| Q3 2021 | $3,547,000 | -8.7% | 95,158 | 0.0% | 0.01% | -7.1% |
| Q2 2021 | $3,884,000 | +20.3% | 95,158 | 0.0% | 0.01% | +7.7% |
| Q1 2021 | $3,229,000 | +6.7% | 95,158 | 0.0% | 0.01% | -7.1% |
| Q4 2020 | $3,026,000 | +45.1% | 95,158 | +17.1% | 0.01% | +27.3% |
| Q3 2020 | $2,086,000 | +26.8% | 81,275 | +26.8% | 0.01% | +22.2% |
| Q2 2020 | $1,645,000 | +67.0% | 64,096 | 0.0% | 0.01% | +28.6% |
| Q1 2020 | $985,000 | -42.9% | 64,096 | +27.6% | 0.01% | -22.2% |
| Q4 2019 | $1,724,000 | +104.8% | 50,243 | -55.4% | 0.01% | +125.0% |
| Q3 2019 | $842,000 | -9.0% | 112,655 | +58.1% | 0.00% | -20.0% |
| Q2 2019 | $925,000 | -1.9% | 71,262 | -8.0% | 0.01% | 0.0% |
| Q1 2019 | $943,000 | +17.9% | 77,422 | +10.3% | 0.01% | 0.0% |
| Q4 2018 | $800,000 | -47.5% | 70,222 | 0.0% | 0.01% | -37.5% |
| Q3 2018 | $1,524,000 | +3.7% | 70,222 | -15.5% | 0.01% | +14.3% |
| Q2 2018 | $1,469,000 | -16.1% | 83,122 | 0.0% | 0.01% | -22.2% |
| Q1 2018 | $1,750,000 | +74.7% | 83,122 | +20.1% | 0.01% | +80.0% |
| Q4 2017 | $1,002,000 | -8.2% | 69,191 | 0.0% | 0.01% | -16.7% |
| Q3 2017 | $1,092,000 | +14.9% | 69,191 | -9.6% | 0.01% | +100.0% |
| Q2 2017 | $950,000 | +52.7% | 76,552 | +100.0% | 0.00% | 0.0% |
| Q1 2017 | $622,000 | +27.5% | 38,276 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $488,000 | +10.2% | 38,276 | +31.7% | 0.00% | 0.0% |
| Q3 2016 | $443,000 | -60.7% | 29,057 | 0.0% | 0.00% | -57.1% |
| Q2 2016 | $1,128,000 | +39.6% | 29,057 | 0.0% | 0.01% | +40.0% |
| Q1 2016 | $808,000 | -42.7% | 29,057 | +10.8% | 0.01% | -44.4% |
| Q4 2015 | $1,411,000 | +5.9% | 26,235 | -21.1% | 0.01% | +12.5% |
| Q3 2015 | $1,332,000 | +42.5% | 33,260 | +13.7% | 0.01% | +60.0% |
| Q2 2015 | $935,000 | +33.8% | 29,260 | 0.0% | 0.01% | +25.0% |
| Q1 2015 | $699,000 | – | 29,260 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |